PD71-08 ANDROGEN RECEPTOR SPLICE VARIANT 7 (AR-V7) IN PATIENTS WITH LOCAL ADVANCED, METASTATIC AND CRPCM: A NOVEL CAPILLARY NANO-INMUNOASSAY TECHNIQUE

Abstract

You have accessJournal of UrologyProstate Cancer: Markers III1 Apr 2017PD71-08 ANDROGEN RECEPTOR SPLICE VARIANT 7 (AR-V7) IN PATIENTS WITH LOCAL ADVANCED, METASTATIC AND CRPCM: A NOVEL CAPILLARY NANO-INMUNOASSAY TECHNIQUE ALVARO RODRIGUEZ, JUAN LUIS GARCIA, JAVIER GARCIA GARCIA, REBECA LOZANO MEJORADA, IRENA MISIEWICZ-KRZEMINSKA, MANUEL HERRERO POLO, JUAN JESUS CRUZ, and FRANCISCO GOMEZ VEIGA ALVARO RODRIGUEZALVARO RODRIGUEZ More articles by this author , JUAN LUIS GARCIAJUAN LUIS GARCIA More articles by this author , JAVIER GARCIA GARCIAJAVIER GARCIA GARCIA More articles by this author , REBECA LOZANO MEJORADAREBECA LOZANO MEJORADA More articles by this author , IRENA MISIEWICZ-KRZEMINSKAIRENA MISIEWICZ-KRZEMINSKA More articles by this author , MANUEL HERRERO POLOMANUEL HERRERO POLO More articles by this author , JUAN JESUS CRUZJUAN JESUS CRUZ More articles by this author , and FRANCISCO GOMEZ VEIGAFRANCISCO GOMEZ VEIGA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.3175AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The androgen receptor (AR) splice variant 7 (AR-V7), has been associated with increased risk of prostate cancer (PC) and with the possibility of progression and responsiveness to the various lines of hormonal treatment and chemotherapy. The aim of this study was to investigate the feasibility of a novel capillary nano-immunoassay in detecting AR-V7 variant in plasma from PC patients METHODS 72 patients with PC were enrolled. Localized, locally advanced, metastasic and CPRC status were allowed due to represent all the PC biological spectrum. Capillary Electrophoresis with immunoassay methodology were performed using the WES (TM) machine according to the manufacturer′s protocol. With this technique, proteins are separated by size, immobilized and probed with specific antibodies. Signal intensity is detected by a horseradish peroxidase-conjugated chemiluminescence system and the data is shown as an electropherogram. The primary antibody used was AR-V7. Quantitative analysis for AR-V7 protein peak was done automatically as area under the peak. Dates from the human prostate cell lines PC3 and VCaP and from 17 healthy donors were used to standardize the assays for AR-V7. The study was carried out in accordance with the ethical standards of the Declaration of Helsinki and was approved by the Institutional Review Board of the University Hospital of Salamanca (Spain). RESULTS AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score ≥ 7, 15 (71%) castration-resistant prostate cancer (CRPC) and 18 (86%) metastatic disease. The complete results are shown in the table 1. CONCLUSIONS This study describes the feasibility of detecting AR-V7 expression from plasma of PC patients by using an automated capillary nano-immunoassay technique WESTM. We provide evidence about this technique, simpler, faster and we have automated platform to make it in comparison with traditional CTCs techniques. AR-V7 has been observed more frequently in aggressive tumors. These findings lay the foundations for liquid biopsy as a means of obtaining biological data in a more convenient way for the patient. These data are needed for personalized treatment decisions, which can prevent patients from receiving inefficient systemic therapy. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1358 Advertisement Copyright & Permissions© 2017MetricsAuthor Information ALVARO RODRIGUEZ More articles by this author JUAN LUIS GARCIA More articles by this author JAVIER GARCIA GARCIA More articles by this author REBECA LOZANO MEJORADA More articles by this author IRENA MISIEWICZ-KRZEMINSKA More articles by this author MANUEL HERRERO POLO More articles by this author JUAN JESUS CRUZ More articles by this author FRANCISCO GOMEZ VEIGA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...